Skip to main content
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. — Investor Relations & Filings

Ticker · GLUE ISIN · US61225M1027 US Manufacturing
Filings indexed 324 across all filing types
Latest filing 2024-10-30 Director's Dealing
Country US United States of America
Listing US GLUE

About Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com/

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops small molecule precision medicines known as molecular glue degraders (MGDs). The company's proprietary drug discovery platform is engineered to rationally design MGDs that leverage the body's natural protein disposal system to selectively eliminate disease-causing proteins. This approach targets proteins that have been historically considered "undruggable" or are inadequately addressed by existing therapies. By integrating expertise in chemistry, artificial intelligence, structural biology, and proteomics, Monte Rosa is advancing a pipeline of therapeutic candidates primarily for cancer and other serious diseases.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2024-10-30 English
Regulatory Filings 2024
Regulatory Filings
2024-10-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text describes the entry into a material definitive agreement between Monte Rosa Therapeutics and Novartis, detailing licensing terms, payments, and responsibilities. It also includes a press release as an exhibit. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a significant corporate event, specifically a licensing agreement, which fits the category of Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not fit other categories. The document length (7727 characters) and content confirm it is not merely an announcement of a report but a substantive filing about a material agreement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-10-28 English
SC 13D/A
Major Shareholding Notification
2024-09-24 English
4
Director's Dealing
2024-09-24 English
4
Director's Dealing
2024-09-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.